Pharmadrug (CSE: BUZZ – OTC: LMLLF) CEO Daniel Cohen joined Steve Darling from Proactive to share news the company has engaged a respected contract research organization with deep expertise in preclinical oncology model development and drug testing, to evaluate the Company's patented enteric-coated formulation of Cepharanthine in a broad panel of human cancers.
Cohen telling Proactive the company is still committed to Cepharanthine in the treatment of esophageal cancer but also sees the benefit of looking at Cepharanthine and assessing potential benefit across a panel of untested cancer types.